Mycophenolic acid (cellcept and myofortic) induced injury of the upper gi tract

American Journal of Surgical Pathology

Volumn 33, Issue 9, 2009, Pages 1355-1363

  Nguyen, Thong ^a   Park, Jason Y ^a   Scudiere, Jennifer R ^a   Montgomery, Elizabeth ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Drug toxicity; Medication associated injury; Mycophenolate mofetil

Indexed keywords

ALCIAN BLUE; EOSIN; HEMATOXYLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYOFORTIC; PERIODIC ACID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; APOPTOSIS; ARTICLE; CELL COUNT; CHRONIC DISEASE; CHRONIC GASTRITIS; CLINICAL ARTICLE; COLON; COLON INJURY; DEGENERATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DUODENITIS; DUODENUM BIOPSY; DYSPEPSIA; DYSPHAGIA; EROSION; ESOPHAGITIS; ESOPHAGUS BIOPSY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HELICOBACTER PYLORI; HEMATEMESIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE CRYPT; KIDNEY TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; STOMACH BIOPSY; STOMACH DISEASE; STOMACH PARIETAL CELL; ULCER; UPPER GASTROINTESTINAL TRACT; UPPER GASTROINTESTINAL TRACT INJURY; VOMITING;

ADULT; AGED; APOPTOSIS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; UPPER GASTROINTESTINAL TRACT; YOUNG ADULT;

EID: 70249143672     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181a755bd     Document Type: Article

References (32)

1. Agarwal DK, Gulati S, Mehta A, et al. Mycophenolate mofetil as an effective alternative to cyclosporin in post-transplant haemolytic uraemic syndrome. Nephrol Dial Transplant. 2000;15:2064-2065.
2. Akram S, Murray JA, Pardi DS, et al. Adult autoimmune enteropathy: Mayo Clinic Rochester experience. Clin Gastroenterol Hepatol. 2007;5:1282-1290; quiz 1245.
3. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005;80:S181-S190.
4. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. 2001; 24:645-663.
5. Behrend M, Braun F. Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. Drugs. 2005;65:1037-1050.
6. Benatar M, Rowland LP. The muddle of mycophenolate mofetil in myasthenia. Neurology. 2008;71:390-391.
7. Chan TM. Mycophenolate mofetil in the treatment of lupus nephritis-7 years on. Lupus. 2008;17:617-621.
8. Daniels JA, Lederman HM, Maitra A, et al. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am J Surg Pathol. 2007;31:1800-1812.
9. Dede F, Onec B, Ayli D, et al. Mycophenolate mofetil treatment of crescentic Henoch-Schonlein nephritis with IgA depositions. Scand J Urol Nephrol. 2008;42:178-180.
10. Ducloux D, Ottignon Y, Semhoun-Ducloux S, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation. 1998;66: 1115-1116.
11. Ducloux D, Motte G, Billerey C, et al. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Transpl Int. 2002;15:387-392.
12. Esmaili N, Chams-Davatchi C, Valikhani M, et al. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent. Eur J Dermatol. 2008;18:159-164.
13. Fecker LF, Stockfleth E, Nindl I, et al. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol. 2007;156(suppl 3): 25-33.
14. Goldstein NS, Underhill J. Morphologic features suggestive of gluten sensitivity in architecturally normal duodenal biopsy specimens. Am J Clin Pathol 2001;116:63-71.
15. Jana NR. NSAIDs and apoptosis. Cell Mol Life Sci. 2008;65: 1295-1301.
16. Lu F, Tu Y, Peng X, et al. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus. 2008;17:622-629.
17. Papadimitriou JC, Drachenberg CB, Beskow CO, et al. Graft-versus-host disease-like features in mycophenolate mofetil-related colitis. Transplant Proc. 2001;33:2237-2238.
18. Papadimitriou JC, Cangro CB, Lustberg A, et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host diseaselike pattern. Int J Surg Pathol. 2003;11:295-302.
19. Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol. 2008;32:1367-1372.
20. Schlaak M, Friedlein H, Kauer F, et al. Successful therapy of a patient with therapy recalcitrant generalized bullous scleroderma by extracorporeal photopheresis and mycophenolate mofetil. J Eur Acad Dermatol Venereol. 2008;22:631-633.
21. Scotiniotis IA, Rokkas T, Furth EE, et al. Altered gastric epithelial cell kinetics in Helicobacter pylori-associated intestinal metaplasia: implications for gastric carcinogenesis. Int J Cancer. 2000;85: 192-200.
22. Snover DC. Mucosal damage simulating acute graft-versus-host reaction in cytomegalovirus colitis. Transplantation. 1985;39: 669-670.
23. Snover DC, Weisdorf SA, Vercellotti GM, et al. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol. 1985;16:387-392.
24. Swartz RD, Lake AM, Roberts WW, et al. Idiopathic retro-peritoneal fibrosis: a role for mycophenolate mofetil. Clin Nephrol. 2008;69:260-268.
25. Trachtman H, Christen E, Frank R, et al. Pilot study of mycophenolate mofetil for treatment of kidney disease due to congenital urinary tract disorders in children. Am J Kidney Dis. 2008;52:706-715.
26. Ugrasbul F, Moore WV, Tong PY, et al. Prevention of diabetes: effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB rat. Pediatr Diab. 2008;9:596-601.
27. Weisdorf DJ, Snover DC, Haake R, et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood. 1990;76:624-629.
28. Welch DC, Wirth PS, Goldenring JR, et al. Gastric graft-versus-host disease revisited: does proton pump inhibitor therapy affect endoscopic gastric biopsy interpretation? Am J Surg Pathol. 2006;30:444-449.
29. Wilkins MR, Dart JK. Mycophenolate mofetil for the treatment of severe inflammatory external eye diseases. Br J Ophthalmol. 2008;92:578-579.
30. Yalcindag FN, Amer R, Forrester JV. Mycophenolate mofetil in the treatment of ocular inflammation in ANCA-associated vasculitis. J Ocul Pharmacol Ther. 2008;24:249-254.
31. Yang YF, Tan DM, Xie YT, et al. Mycophenolate mofetil prevents lethal acute liver failure in mice induced by bacille Calmette-Guerin and lipopolysaccharide. J Gastroenterol Hepatol. 2008;23:611-618.
32. Zolezzi M. Mycophenolate sodium versus mycophenolate mofetil: a review of their comparative features. Saudi J Kidney Dis Transpl. 2005;16:140-145.